The End Of The Blockbuster? Implications For Pricing Of New Drugs
Health Affairs - June 16, 2014
The productivity slowdown in drug innovation has been identified and widely discussed in recent years. In addition, the stagnation in the number of novel drugs (new molecular entities and new biologics) approved by the U.S. Food and Drug Administration (FDA) has also been well-documented. Less well-appreciated, however, is the decline in the “applicability” of new drug approvals.
How to start bringing down specialty drug costs
Healthcare Payer News - June 12, 2014
Sovaldi has brought high prices of specialty drugs to the fore. Less examined so far are proactive approaches insurers and drug benefits managers can use to curb the growth trend without sacrificing quality or access.
Report: U.S. Ranks Last Among 11 Countries for Health Care Quality
California Healthline - June 16, 2014
The U.S. health care system again ranked last among 11 western, industrialized nations, despite spending far more on health care per capita, according to a report from the Commonwealth Fund, the Washington Post's "To Your Health" reports (Bernstein, "To Your Health," Washington Post, 6/16).
Moody's: New cancer drugs represent significant growth opportunity
Drug Store News - June 13, 2014
New approaches to treating cancer are creating big growth opportunities for the pharmaceutical industry, Moody's Investors Service stated in a report released Thursday titled "Cancer Breakthroughs Bring New Options for Patients and Revenue Streams to Big Pharma."
Walmart's first owned health clinic could mean big changes ahead for convenient care industry
Drug Store News - June 13, 2014
Walmart has opened in Copperas Cove, Texas, its first owned healthcare clinic.
Biogen, AbbVie drug slows MS episodes, safety issues recur
Reuters - June 16, 2014
A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.
What’s up with Big Pharma?
Houston Chronicle - June 9, 2014
Every day, low-income patients at several Houston-area hospitals are helped by a federal program they've never heard of. The 340B drug discount program helps them get discounted medications and underwrites free clinics and health services around the city.
Switching To Less Expensive Blindness Drug Could Save Medicare Part B $18 Billion Over A Ten-Year Period
Health Affairs - June, 2014
The biologic drugs bevacizumab and ranibizumab have revolutionized treatment of diabetic macular edema and neovascular age-related macular degeneration, leading causes of blindness... However, at $2,023 per dose, ranibizumab costs forty times more than bevacizumab.
Trying to Limit Outside Influence in Prescribing Drugs
The Texas Tribune - June 16, 2014
As sales representatives for pharmaceutical companies brought doughnuts and lunch over the years to physicians at the 20 Kelsey-Seybold medical clinics in the Houston area, Patrick Carter worked to limit their presence.
Researchers urge specialty Rx insurance plans
Medical Marketing & Media - June 10, 2014
Researchers at the University of Michigan's School of Public Health argue in a recent study that taking a personalized approach to specialty medications could be a key to saving healthcare dollars over the long-term.
State lawmakers tackle public health issues
USA TODAY - June 10, 2014
Four years into implementing the Affordable Care Act, state politicians turned their attention to other pressing health care issues such as preventing drug overdose deaths, limiting e-cigarettes and making medical marijuana more available.
Drug Delays Cost U.S. Health-Care Payers Millions of Dollars (WSJ subscription required)
Wall Street Journal - June 17, 2014
Manufacturing issues hold up production of generic versions of blockbuster drugs
Alzheimer's Drug Tested on Healthy Seniors with Risk Factors
Associated Press - June 9, 2014
In one of the most ambitious attempts yet to thwart Alzheimer's disease, a major study got underway Monday to see if an experimental drug can protect healthy seniors whose brains harbor silent signs that they're at risk.
Two Smoking Treatments Are Better Than One
Duke Medicine - June 17, 2014
Combining two smoking cessation therapies is more effective than using just one for male and highly nicotine-dependent smokers who weren't initially helped by the nicotine patch, according to researchers at Duke Medicine.
Contact,
Kristin LaVitola
Marketing Director, PSG
Pharmaceutical Strategies Group (PSG)
Office: 972-244-8388
Email: KLavitola@PSGConsults.com
PSGNewsletter@PSGConsults.com
www.PSGConsults.com
 |
 |
 |